Taft is pleased to have acted as legal counsel to Nimble Therapeutics in its sale to AbbVie (NYSE: ABBV). Nimble is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics. AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. Read the release here.

Taft’s core deal team was led by Sara Kruse and included Josh Borson, Marko Belej, Jeanne Cors, Chris Fowler, Bridget Tignanelli, Nick Binder, Aaron Miller, and Summer Moukalled.